ArticleFrontiers in endocrinology2025
The impact of different ovarian stimulation protocols on the expression levels of GDF-9 and BMP-15 in cumulus cells of follicles.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of two novel PATL2 variants and transcriptome sequencing reveals their role in oocyte maturation.Journal of ovarian research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the expression levels of the oocyte-secreted factors growth differentiation factor-9 (GDF-9) and bone morphogenetic protein-15 (BMP-15) in cumulus cells (CCs) under different controlled ovarian stimulation (COS) protocols and their association with oocyte maturity and embryo developmental potential. Methods: This study included 76 patients requiring intracytoplasmic sperm injection (ICSI) due to severe oligoasthenoteratozoospermia or previous ICSI treatment, resulting in the collection of 749 CC samples. Patients were divided into four groups based on COS protocols: short-acting luteal phase (14 patients, 168 CCs), long-acting follicular phase (21 patients, 189 CCs), micro-stimulation (12 patients, 86 CCs) and antagonist (29 patients, 306 CCs). The mRNA was extracted from cumulus granulosa cells, and the relative levels of GDF-9 and BMP-15 were measured using real-time quantitative PCR (Q-PCR). The expression levels of GDF-9 and BMP-15 were compared across different ovarian stimulation protocols, while oocyte maturation, fertilization, cleavage, and blastocyst formation were assessed. The expression levels of GDF-9 and BMP-15 were compared across protocols, and oocyte maturation, fertilization, cleavage and blastocyst formation were assessed. Results: GDF-9 and BMP-15 levels were substantially higher in MII oocytes than in MI and GV oocytes and were also elevated in the normal fertilization group, high-quality cleavage embryos and high-quality blastocysts. Growth differentiation factor-9 expression was higher in the short-acting luteal phase protocol than in the antagonist protocol, whereas BMP-15 expression was higher in both the short-acting luteal phase and long-acting follicular phase protocols compared with the micro-stimulation and antagonist groups. Conclusion: GDF-9 and BMP-15 are reliable indicators of oocyte developmental potential. The long-acting follicular phase and short-acting luteal phase protocols enhance oocyte maturity and embryo development, whereas the micro-stimulation and antagonist protocols appear less favorable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.